BSD Medical Signs Distribution Agreement with and Ships MicroThermX® Microwave Ablation Products to Active Medical Inc.

  BSD Medical Signs Distribution Agreement with and Ships MicroThermX®
  Microwave Ablation Products to Active Medical Inc.

Business Wire

SALT LAKE CITY -- December 11, 2013

BSD Medical Corporation (NASDAQ:BSDM) (Company or BSD) (, a
leading provider of medical systems that utilize heat therapy to treat cancer,
announced today that the Company has signed an agreement with Active Medical,
Inc. (Active) for the sales and distribution of the MicroThermX Microwave
Ablation (MicroThermX) line of products. Pursuant to the agreement, BSD
recently commenced shipment of MicroThermX systems and synchronous phased
array disposable antennas to Active.

Active has an extensive 26-year history selling interventional radiology and
surgical devices produced by some of the leading medical companies in the U.S.
and has successful long-term relationships with these companies. Active has 17
sales personnel specializing in selling innovative surgical and interventional
radiology products.

Based in Harrisburg, Pennsylvania, Active has the rights to market the
MicroThermX^® line of products in Delaware, Maryland, North Carolina,
Pennsylvania, South Carolina, Virginia and West Virginia. These states have a
combined population of approximately 53 million people. The Active sales team
will work in close collaboration with BSD sales management and our direct
sales representatives to penetrate this significant U.S. market opportunity.

“BSD’s partnership with Active Medical is very synergistic as both companies
have products that target the interventional radiology and surgical markets,”
said Brian Ferrand, BSD Vice President of Domestic Sales. “Active already has
the relationships with key interventional radiologists and administrators that
are important for MicroThermX to be successful in the hospital environment. We
expect Active will make a strong contribution toward expanding our MicroThermX
user base in the Eastern U.S. and increasing domestic revenue.”

About the MicroThermX ^  Microwave Ablation System

The MicroThermX Microwave Ablation System is a compact, mobile,
state-of-the-art, proprietary system that includes a microwave generator,
single-patient-use disposable antennas, and a thermistor-based temperature
monitoring system. The innovative design of the MicroThermX ^ is the first of
its kind that allows delivery of higher power levels using a single generator.
The MicroThermX ^ utilizes innovative synchronous phased array technology that
was developed and patented by BSD to provide larger and more uniform zones of
ablation during a single procedure. The MicroThermX product line includes an
innovative, high-end disposable that is used in each ablation treatment, and
provides ongoing revenue streams for BSD. The soft tissue ablation world
market potential is estimated to exceed $2.3 billion. The U.S. Food and Drug
Administration (FDA) has granted the Company a 510(k) clearance to market the
MicroThermX for ablation of soft tissue. BSD has also received CE Marking for
the MicroThermX System, which allows BSD to market the MicroThermX ^ system in
Europe. CE marking is also recognized in many countries outside of the EU,
providing BSD the ability to market the MicroThermX ^ to a number of
international markets.

About BSD Medical Corporation

BSD Medical Corporation develops, manufactures, markets and services systems
to treat cancer and benign diseases using heat therapy delivered using focused
microwave energy and radiofrequency (RF). BSD’s microwave ablation system has
been developed as a stand-alone therapy to ablate and destroy soft tissue.
BSD’s hyperthermia cancer treatment systems, which have been in use for
several years in the United States, Europe and Asia, are used to treat certain
tumors with heat (hyperthermia) while increasing the effectiveness of other
therapies such as radiation therapy. The Company has developed extensive
intellectual property, multiple products in the market and well established
distribution in the United States, Europe and Asia. Certain of the Company’s
products have received regulatory approvals in the United States, Europe and
China. For further information visit BSD Medical's website at

Statements contained in this press release that are not historical facts are
forward-looking statements, as defined in the Private Securities Litigation
Reform Act of 1995. All forward-looking statements are subject to risks and
uncertainties detailed in the Company's filings with the Securities and
Exchange Commission, including the market demand for our MicroThermX products
and the regulatory requirements we face. These forward-looking statements
speak only as of the date on which such statements are made, and the Company
undertakes no obligation to update such statements to reflect events or
circumstances arising after such date, except as required by law.


BSD Medical Corporation
William Barth, 801-972-5555
fax: 801-972-5930
Press spacebar to pause and continue. Press esc to stop.